Company Profile

Codomax Inc
Profile last edited on: 2/7/2024      CAGE: -----      UEI: EV4LS8M87WU7

Business Identifier: Epitranscriptomics-Driven and Computationally Enhanced Biologics
Year Founded
----
First Award
2023
Latest Award
2023
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

17 Briden Street Suite 219
Worcester, MA 01605
   N/A
   info@codomax.com
   www.codomax.com
Location: Single
Congr. District: 02
County: Worcester

Public Profile

Cells uniquely adapt to stressors to reprogram mRNA translation and protein expression. Codomax Inc have cracked this alternative genetic and epitranscriptomic linked code and use an integrated suite of omics tools to measure how translation is reprogrammed during the stress of biomanufacturing and re-engineer cells for maximal protein expression. By measuring how cells respond to stress, our Epi-MAX platform enables efficient production of complex and difficult-to-express proteins via systems-level re-engineering. Company leverages stress-induced translational reprogramming of cells to develop novel biologics and produce difficult-to-express proteins to make them affordable and accessible to all.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 1 NIH $324,999
Project Title: Exploiting translation elongation for improved biologics manufacturing

Key People / Management

  Joseph Reddy -- President and CEO

  Thomas Begley -- Co-Founder and Advisor

  Shane Byrne -- Co-Founder and CSO

  Peter Dedon -- Co-Founder and Advisor

Company News

There are no news available.